X-Message-Number: 27830 Date: Sun, 09 Apr 2006 11:26:48 -0400 From: Keith Henson <> Subject: Cracking the Longevity Code [Probably 6 people will post this--Keith] Long-lived. Photos from 1910 and 1999, showing one of the families that participated in the study. Credit: Keane family Cracking the Longevity Code By Susanne McDowell ScienceNOW Daily News 4 April 2006 Living to a ripe old age takes more than a healthy lifestyle: you've got to have the right combination of genes. The question is, which ones? Scientists now have several promising candidates thanks to the discovery of a gene variation in humans that appears to increase lifespan and lower the risk of cardiovascular diseases. The finding could eventually lead to the development of life-extending drugs. Studies of worms and fruit flies show that variations, or polymorphisms, in a single gene can affect how long these creatures live. Scientists think humans carry tens or even hundreds of related polymorphisms. But they're tough to identify -researchers have found only a few since the mid-1990s. In 2003, Nir Barzilai and Gil Atzmon, who study aging at Albert Einstein College of Medicine in New York, discovered that people with a certain polymorphism of the cholesterol-influencing gene CETP lived longer than those without it (ScienceNOW, October 2003). Now the researchers have identified another part of the longevity code. In a study reported in this month's issue of PLoS Biology, Barzilai and Atzmon examined the genetic makeup of 213 centenarians. All were Ashkenazi Jews, a group with a relatively uniform genetic pool in which differences tend to stand out. The researchers also compared the centenarians' children with a control group comprised of individuals whose parents died before reaching 85. They found that 25% of the centenarians carried a particular variation of the gene APOC3, which helps determine cholesterol levels. The same variation was found in 20% of their children but only 10% of the control group, suggesting that long life runs in families. Those with the polymorphism were 15% less likely to have high blood pressure and had a significantly decreased risk for cardiovascular disease or diabetes. A drug that mimics the function of the CETP gene is already in development, says Atzmon, and the same could happen with APCO3. Eventually multiple gene functions could be simulated by a single pill. "You'd take it once a day like a vitamin," he says. The researchers have done a "remarkable job" of recruiting and studying a rare population, says Thomas Perls, a geriatrician at Boston Medical Center in Massachusetts. What's needed now is confirmation in other groups, says Bard Geesaman, a scientist at Elixir Pharmaceuticals--which develops drugs for age-related diseases--in Cambridge, Massachusetts. And researchers will have to discover many more of the genes involved before they can fully understand their collective impact on health, he says. Full text from ScienceNow http://sciencenow.sciencemag.org/cgi/content/full/2006/404/1?etoc Rate This Message: http://www.cryonet.org/cgi-bin/rate.cgi?msg=27830